CSL Ltd

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

CSL Limited recently closed a license agreement for a haemophilia B gene therapy candidate which is positive, but there are still risks associated with competition and regulatory approvals. The company's near-term outlook is mixed, with the potential upside of increased influenza vaccine demand offset by the prospects of low plasma collection volumes.

CSL Limited: Near-Term Outlook Mixed Despite New License Agreement

KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more than 82,000 high-risk patients with recent acute coronary syndrome (ACS).

New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days

NEW YORK, May 14, 2021 /PRNewswire/ -- Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a global biotherapeutics leader driven by its promise to save and improve lives, are excited to announce that Dr. Minnie Sarwal of NephroSant was selected as the winner of the Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation. Dr. Minnie Sarwal of NephroSant wins the 2021 Lyfebulb / CSL Behring Innovation Challenge in Transplantation NephroSant will receive the $25,000 monetary award to further develop diagnostic tools for early detection and lifetime monitoring of kidney health and injury, including a non-invasive transplant rejection test designed specifically for kidneys.

Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation Challenge

Humana

M3 Inc

Thermo Fisher Scientific

UnitedHealth Group

Investors may be interested in the following health care companies, as they have expanded their revenue per share and Ebitda per share by more than 10% over the trailing five-year and 10-year periods through April 28.

5 Health Care Stocks Growing Fast

CSL Limited (CSLLY) CEO Paul Perreault on Q2 2021 Results - Earnings Call Transcript

Merck

Sanofi

Their coronavirus projects fell behind, faltered, or failed.

News for CSL Ltd Stock (CSLLY)